Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
Author:
Affiliation:
1. Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd, Hwaseong 18469, Korea.
2. College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.
Publisher
The Korean Physiological Society and The Korean Society of Pharmacology
Subject
Pharmacology,Physiology
Link
https://synapse.koreamed.org/pdf/10.4196/kjpp.2019.23.1.55
Reference32 articles.
1. Diagnosis and Classification of Diabetes Mellitus
2. Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
3. Postprandial Hyperglycemia and Diabetes Complications
4. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
5. Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus;Current Drug Targets;2023-08-03
2. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans;Molecular Metabolism;2020-12
3. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors;Bioorganic & Medicinal Chemistry Letters;2020-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3